90Y-ibritumomab tiuxetan
Trials 13
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 90Y-ibritumomab tiuxetan | “90Y-ibritumomab tiuxetan is designed to attach to lymphoma cells and destroy the cells using a radioactive particle that is attached to it.” NCT01490723 ↗6“Combining 90Y-ibritumomab Tiuxetan With High-dose Chemotherapy” NCT00336843 ↗ “90Y-Ibritumomab tiuxetan, 0.4 mCi/kg, I.V.” NCT00336843 ↗ |
| Known as | (90)Y-IT | “PURPOSE: We report an international, multicenter phase II trial to evaluate the efficacy and toxicity of fractionated (90)Y-ibritumomab tiuxetan ((90)Y-IT) as initial therapy...” PMID 24297953 ↗ Dec 2013 |
| Known as | 90Y-ibritumomab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00761384 ↗ |
| Known as | Yttrium Y-90 Ibritumomab Tiuxetan | “Radiolabeled monoclonal antibodies, such as yttrium Y 90 ibritumomab tiuxetan, can find cancer cells and carry cancer-killing substances to them without harming normal cells.” NCT00397800 ↗5“Patients receive yttrium Y 90 ibritumomab tiuxetan intravenously (IV) following rituximab IV on day -14.” NCT00695409 ↗ “Yttrium Y-90 Ibritumomab Tiuxetan” NCT01434472 ↗ “Yttrium Y-90 Ibritumomab Tiuxetan” NCT02320292 ↗ |
| Known as | yttrium-90-ibritumomab tiuxetan | “Two Repeated Doses of Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) as Salvage Treatment for Patients With Relapsed or Refractory Aggressive B-cell Lymphoma: a Phase II Study.” NCT00902525 ↗1“Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation” PMID 19547918 ↗ Jun 2009 |
| Known as | Zevalin | “90Y-ibritumomab tiuxetan (Zevalin) at 0.4 mCi/kg is administered one week prior to start high-dose chemotherapy (BEAM/BEAC) in patients who have not achieved CR after induction therapy.” NCT00514475 ↗2“Two Repeated Doses of Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) as Salvage Treatment for Patients With Relapsed or Refractory Aggressive B-cell Lymphoma: a Phase II Study.” NCT00902525 ↗ “90Y-ibritumomab tiuxetan (Zevalin)” NCT00414089 ↗ |
| Action | Inhibit | “Monoclonal antibodies, such as rituximab and yttrium Y 90 ibritumomab tiuxetan, can block cancer growth in different ways.” NCT00310128 ↗ |
| Modality | Monoclonal antibody | “Monoclonal antibodies, such as rituximab and yttrium Y 90 ibritumomab tiuxetan, can block cancer growth in different ways.” NCT00310128 ↗ |
| Route | Intravenous | “yttrium Y 90 ibritumomab tiuxetan (IDEC-90Y2B8) IV over 10 minutes on day 8” NCT00012298 ↗ |